Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT)
Фармацевтический хондроитинсульфат столь же эффективен, как целекоксиб, и превосходит плацебо при симптоматическом остеоартрите коленного сустава: исследование ChONdroitin versus CElecoxib versus Placebo (CONCEPT)
2017-05-23
SCID: 54.1/nwe5gngs
Discuss with AI
Lequesne IndexVisual Analogue Scalecelecoxibknee osteoarthritispharmaceutical-grade chondroitin sulfate
Figures from the paper
Abstract (AI)
OBJECTIVES: Chondroitin sulfate 800 mg/day (CS) pharmaceutical-grade in the management of symptomatic knee osteoarthritis consistent with the European Medicines Agency guideline. METHODS: A prospective, randomised, 6-month, 3-arm, double-blind, double-dummy, placebo and celecoxib (200 mg/day)-controlled trial assessing changes in pain on a Visual Analogue Scale (VAS) and in the Lequesne Index (LI) as coprimary endpoints. Minimal-Clinically Important Improvement (MCII), Patient-Acceptable Symptoms State (PASS) were used as secondary endpoints. RESULTS: 604 patients (knee osteoarthritis) diagnosed according to American College of Rheumalogy (ACR) criteria, recruited in five European countries and followed for 182 days. CS and celecoxib showed a greater significant reduction in pain and LI than placebo. In the intention-to-treat (ITT) population, pain reduction in VAS at day 182 in the CS group (-42.6 mm) and in celecoxib group (-39.5 mm) was significantly greater than the placebo group (-33.3 mm) (p=0.001 for CS and p=0.009 for celecoxib), while no difference observed between CS and celecoxib. Similar trend for the LI, as reduction in this metric in the CS group (-4.7) and celecoxib group (-4.6) was significantly greater than the placebo group (-3.7) (p=0.023 for CS and p=0.015 for celecoxib), no difference was observed between CS and celecoxib. Both secondary endpoints (MCII and PASS) at day 182 improved significantly in the CS and celecoxib groups. All treatments demonstrated excellent safety profiles. CONCLUSION: A 800 mg/day pharmaceutical-grade CS is superior to placebo and similar to celecoxib in reducing pain and improving function over 6 months in symptomatic knee osteoarthritis (OA) patients. This formulation of CS should be considered a first-line treatment in the medical management of knee OA.
Key Findings
1
All treatments demonstrated excellent safety profiles, supporting pharmaceutical-grade chondroitin sulfate as a potential first-line treatment for symptomatic knee osteoarthritis.
2
At day 182, pain reduction was −42.6 mm with chondroitin sulfate, −39.5 mm with celecoxib, and −33.3 mm with placebo; neither active treatment differed significantly.
3
Both chondroitin sulfate and celecoxib significantly improved Minimal-Clinically Important Improvement and Patient-Acceptable Symptoms State outcomes at day 182.
4
Chondroitin sulfate and celecoxib significantly improved Lequesne Index scores versus placebo, with reductions of −4.7, −4.6, and −3.7 points, respectively.
5
In a 6-month randomized controlled trial of 604 knee osteoarthritis patients, pharmaceutical-grade chondroitin sulfate significantly reduced pain versus placebo.
Research Object
symptomatic knee osteoarthritis patients treated with pharmaceutical-grade chondroitin sulfate, celecoxib, or placebo
Research Subject
comparative effects on pain, physical function, clinically important improvement, and patient-acceptable symptom state over 6 months
Publication Details
Publication Date
2017-05-23
Journal
Publisher
ISSN
Cited by
132
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai2
American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee2012
An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)2014
Cited by3
An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)2019
Osteoarthritis: Epidemiology, Pathogenesis, and Treatment2026
Access to Highly Purified Chondroitin Sulfate for Appropriate Treatment of Osteoarthritis: A Review2017